Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affinia Therapeutics Closes $110 Million Series B Financing
Affinia TherapeuticsMay 3, 2021 GMT Financing co-led by EcoR1 Capital and Farallon Capital Management
Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Cap
Published: Feb 19, 2021 By Alex Keown
PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis.
Samir Mody as chief commercial officer, while
Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped
Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx.
> Antios Therapeutics has tapped
Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics.